Merck spends $10 billion for Verona, gaining access to its COPD medication
With the acquisition, Merck gets access to Verona Pharma's chronic obstructive pulmonary disease medication Ohtuvayre. The Food and Drug Administration approved Ohtuvayre in June 2024 for the maintenance treatment of COPD in adults.
'Ohtuvayre complements and expands our pipeline and portfolio of treatments for cardio-pulmonary diseases while delivering near- and long-term growth as well as value for shareholders," Merck Chairman and CEO Robert Davis said in a statement.
"We believe Merck's commercial footprint and industry-leading clinical capabilities will help accelerate the potential of Ohtuvayre to reach more patients living with COPD," Verona Pharma President and CEO David Zaccardelli said.
The deal, which was approved by the boards of both companies, is expected to close in the fourth quarter. It still needs approval of Verona Pharma shareholders and sanction by the High Court of Justice of England and Wales.
Sign in to access your portfolio
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Verona Pharma plc (VRNA): A Bull Case Theory
We came across a bullish thesis on Verona Pharma plc (VRNA) on Capital Employed's Substack by Patients Capital Management. In this article, we will summarize the bulls' thesis on VRNA. Verona Pharma plc (VRNA)'s share was trading at $91.53 as of 3rd July. A patient in a clinic, taking a medication dose from a nebulizer to treat a respiratory disease. Verona Pharma, a UK-based biopharmaceutical company, is advancing a standout therapeutic with its lead asset, Ohtuvayre, poised to redefine treatment for COPD and related respiratory diseases. The most compelling data point is patient feedback: individuals using Ohtuvayre report feeling noticeably better, which is critical in COPD where managing daily wellbeing matters most. Ohtuvayre's non-steroidal mechanism means it can be safely combined with all existing COPD medications, creating effectively zero competition and addressing a major unmet need by avoiding the downsides of chronic steroid therapies. Beyond COPD, Verona Pharma retains significant upside from potential indications in non-CF bronchiectasis and asthma, which remain largely unpriced in current valuations and could offer meaningful long-term growth—serving as optionality embedded in the investment thesis. Strategically, the company is positioning for partnerships by developing dry powder inhaler (DPI) and metered dose inhaler (MDI) formulations, creating a clear window for larger pharmaceutical companies to engage in due diligence or acquisition discussions. Importantly, Verona Pharma carries no near-term financing overhang, eliminating a common investor concern and making potential deal outcomes even more impactful. Despite a strong rally in the stock, the market still appears to underappreciate Verona Pharma's potential: analysts are currently modeling peak sales of around $2.5 billion, even though the nebulized version alone could realistically reach $4–5 billion. As sell-side estimates adjust quarterly to reflect this upside, the stock is likely to re‐rate. Looking ahead, growing investor conviction and evolving shareholder base could provide deeper support for higher valuation levels. With differentiated clinical efficacy, broad strategic optionality, strong balance sheet, and significant valuation mispricing, Verona Pharma offers a compelling multi-catalyst investment opportunity in respiratory therapeutics. Previously, we covered a on Teva Pharmaceutical Industries Limited (TEVA) by Kontra in May 2025, which highlighted the company's transformation under CEO Richard Francis, strong free cash flow growth, and rising contributions from innovative drugs like Austedo and Uzedy. The company's stock price has been stable with an approximate 0.7% gain since our coverage. This is because the thesis has yet to fully play out but remains valid given Teva's ongoing operational momentum and valuation support. Patients Capital Management shares a similar view on Verona Pharma but emphasizes a more targeted bet on a single asset, Ohtuvayre, with blockbuster potential and strategic optionality in respiratory therapeutics. VRNA isn't on our list of the 30 Most Popular Stocks Among Hedge Funds. While we acknowledge the risk and potential of VRNA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Assay Kit Demand Surges as Advancements in Omics Technologies Elevate Biomarker Discovery and Diagnostic Precision
The biomarkers market is poised to grow from USD 62.39 billion in 2025 to USD 104.15 billion by 2030, with a CAGR of 10.8%. This growth is driven by the advantages of assay kits and advancements in genomics, proteomics, and next-generation sequencing, leading to novel biomarker development. Predictive biomarkers are dominant in efficacy biomarkers due to their role in guiding treatment decisions, particularly in oncology and autoimmune diseases. The immunoassays segment led the market in 2024, supported by its high specificity in detecting diverse biomarkers. The Asia Pacific region is set to experience the highest CAGR due to a large patient base and supportive healthcare policies. Key players include Roche, Merck, and Abbott. The report offers detailed analysis, competitive assessment, and insights into market trends and strategies. Biomarkers Market Dublin, July 09, 2025 (GLOBE NEWSWIRE) -- The "Biomarkers Market by Offering, Type, Research Area, Technology, Disease, Application - Global Forecast to 2030" has been added to offering. The biomarkers market is on a robust growth trajectory, projected to escalate from USD 62.39 billion in 2025 to USD 104.15 billion by 2030, marked by a CAGR of 10.8%. The report provides an exhaustive overview of industry trends, challenges, and growth opportunities, offering stakeholders insights to devise strategic initiatives aligning with the market pulse. It discusses market diversification, including innovative product launches and the competitive landscape with assessments of companies such as Charles River Laboratories, Bio-Rad Laboratories, and more. This expansion is primarily driven by the efficacy of assay kits in delivering standardized and optimized biomarker analysis, further advancing diagnostics and research in healthcare. Enhanced genomics, proteomics, metabolomics, and next-generation sequencing technologies are uncovering biomarkers with improved sensitivity, specificity, and predictive potential. The predictive biomarkers segment dominated the efficacy biomarkers market in 2024. Segmenting the market into safety, efficacy, and validation biomarkers, where efficacy biomarkers split further into predictive, surrogate, pharmacodynamic, and prognostic categories, predictive biomarkers led the market. This is attributed to their ability to enhance clinical outcomes by guiding tailored treatment strategies, particularly in oncology, autoimmune disorders, and infectious diseases. The increased adoption of predictive biomarkers is evident through more companion diagnostic approvals, like Roche's PATHWAY anti-HER2/neu (4B5) test for HER2-low breast cancer, highlighting their significant value in personalized medicine. Immunoassays remained the top choice in the biomarker technologies market in 2024. The technology segment of the market includes immunoassays, NGS, PCR, mass spectrometry, and chromatography. Immunoassays commanded the largest share due to their precise detection capabilities across various diseases such as oncology and cardiology. This has furthered support for precision diagnostics through scalable high-throughput testing. Companies like Roche and Abbott are propelling advances in immunoassay platforms, enhancing diagnostic capacities across disease spectrums. The Asia Pacific region exhibits the highest growth in the biomarker market. The Asia Pacific leads in growth rate, fueled by a large patient base and supportive healthcare initiatives focusing on cancer care enhancements. Accelerated pharmaceutical and biotechnology research in developing novel drug therapies also contribute to this growth, increasing demand for biomarkers that facilitate drug discovery and development efforts. Primary insights from study interviews: Analysis indicates 44% engagement from tier 1 companies, with North America comprising 40% of the study interviews. Key player profiles include F. Hoffmann-La Roche Ltd, Merck KGaA, Thermo Fisher Scientific Inc., Abbott, and other major market influencers. Focus areas include company strategies, partnerships, and recent market developments. Key Attributes: Report Attribute Details No. of Pages 560 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $62.39 Billion Forecasted Market Value (USD) by 2030 $104.15 Billion Compound Annual Growth Rate 10.8% Regions Covered Global Market Dynamics Market Drivers Increasing Use of Biomarkers in Drug Discovery & Development Growing Importance of Companion Diagnostics Rising Prevalence of Cancer Development of Biomarkers for Rare Diseases Increasing Funds and Grants for Biomarker Research Advancement in Omics Technologies Restraints High Capital Investments and Extensive Timelines for Biomarker Development Disease Complexity and Heterogeneity Opportunities Growing Preference for Personalized Medicine and Precision Oncology Enhanced Collaboration Among Healthcare Providers and Key Industry Players High Growth Potential of Emerging Economies Challenges Issues Associated with Quantification & Validation of Biomarkers Complexities Associated with Data Set Integration Technical Issues Related to Sample Collection and Storage Company Profiles Thermo Fisher Scientific Inc. Merck KGaA F. Hoffmann-La Roche Ltd. Qiagen Abbott Agilent Technologies, Inc. Revvity Inc. Charles River Laboratories Bio-Rad Laboratories, Inc. Eurofins Scientific Biomerieux Illumina, Inc. Jsr Corporation Guardant Health Labcorp Quanterix Meso Scale Diagnostics, LLC Other Players Celerion Standard Biotools Sebia Bioagilytix Labs Stressmarq Biosciences Inc. Northeast Bioanalytical Laboratories LLC Signosis Serimmune Theraindx Lifesciences Pvt. Ltd. Synexa Life Sciences Bv Diatech Pharmacogenetics Singulex, Inc. R-Biopharm AG For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Biomarkers Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Upturn
5 hours ago
- Business Upturn
Amphista Therapeutics announces achievement of a research milestone in its collaboration with Merck triggering a milestone payment
Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue™ degraders for oncology and immunology indications Cambridge, UK, 16 July 2025 – Amphista Therapeutics ('the Company' or 'Amphista'), a leader in the discovery of next-generation, Targeted Protein Degradation (TPD) medicines, today announces the successful achievement of a discovery research milestone under its exclusive research collaboration and licence agreement with Merck. In conjunction with the milestone achievement, Amphista receives a pre-specified financial payment. The associated target on which the milestone is triggered is currently undisclosed. 'As we continue to build our portfolio of first- and/or best-in-class Targeted Glues™, we are delighted to have reached an important milestone in our collaboration with Merck. The progress we have made together speaks to the effective partnership between scientists from both companies, enabling us to focus on advancing high-quality compounds for further development,' said Antony Mattessich, Chief Executive Officer at Amphista. 'This achievement reinforces the exceptional capabilities of our Eclipsys® platform in the rational design of orally bioavailable protein degraders, bringing us a step closer to improving patient outcomes.' Under the agreement, Amphista is responsible for the discovery and early development of small molecule protein degraders using its Eclipsys® platform. Merck is granted a global exclusive license to the resulting degrader molecules and will be responsible for further development and commercialisation activities. About Amphista Therapeutics At Amphista Therapeutics, we are focused on transforming the lives of patients with severe diseases, including cancer and neurodegenerative disorders, through the discovery of advanced, next generation targeted protein degradation (TPD) medicines. Amphista applies its proprietary Eclipsys® platform to generate unique, sequentially bifunctional Targeted Glue™ therapeutics with a differentiated mechanism and leading drug-like properties. Our portfolio offers the potential to deliver first- and/or best-in-class therapeutics with performance characteristics beyond the limitations of CRBN and VHL-based agents. Amphista was co-founded by Advent Life Sciences and is additionally funded by a premier group of investors including Forbion, Gilde Healthcare, Novartis Venture Fund, SV's Dementia Discovery Fund and Eli Lilly. For more information, please visit: Amphista, Eclipsys, Targeted Glue, Targeted Glues and the Amphista logo are all trademarks or registered trademarks of Amphista Therapeutics Limited. For more information please contact: Amphista TherapeuticsJohn Goodall [email protected]